It may be possible to infer the risk of CRCI by detecting the single‐nucleotide locus of ALDH2 in patients with breast cancer who receive chemotherapy, which is conducive to strengthening clinical interventions for these patients and improving their QOL. This evidence concerns the gene ALDH2 and breast cancer.